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3 cells (RGCs) (Quigley et al., 1995) . Although the most important trigger for progression of glaucomatous damage is an elevation of intraocular pressure (IOP), the exact mechanism remains unknown. Current standard therapy for glaucoma is to lower the IOP by medication or surgery that may delay disease progression but does not alter RGC loss and axon degeneration. Therefore, treatment of glaucomatous neuropathy requires the preservation, protection, and rescue of RGCs. Although several approaches for neuroprotection have been described including the use of neurotrophins (Cui et al., 1998) , no effective clinical neuroprotectants are available.
Neurotrophic agents have been implicated in survival-and growth-promoting activity in the central nerve system (CNS). Brain-derived neurotrophic factor (BDNF)
is an important survival factor for RGCs. BDNF rescues RGCs from death after optic nerve axotomy (Yan et al., 1999; Zhang et al., 2005; Mansour-Robaey et al., 1994; Mey and Thanos, 1993) and in cell culture (Johnson et al., 1986 ). Exogenously applied BDNF can delay the death of RGCs in animal glaucoma models (Ko et al., 2001; Quigley et al., 2000) . However, a series of studies showed that BDNF did not rescue all RGCs after optic nerve axotomy and only delayed RGC death (MansourRobaey et al., 1994; Mey and Thanos, 1993; Peinado-Ramon et al., 1996; . Even repeated intravitreal injections of BDNF, or persistent availability of bioactive BDNF did not promote long-term survival of RGCs after axotomy (Mansour-Robaey et al., 1994; Di et al., 1998; Isenmann et al., 1998) . The protective effect of exogenous BDNF or overexpression of BDNF gene on RGCs was also limited in a chronic glaucoma model (Martin et al., 2003; Ko et al., 2001) . A clearer mechanistic understanding of the limited neuroprotection of BDNF can be crucial for the development of treatments for glaucoma.
LINGO-1 is a leucine-rich repeat Ig-containing protein first identified as a critical component of Nogo receptor /p75 or TROY signaling complexes that prevent
4 axonal regeneration in the presence of myelin inhibitors in the CNS (Shao et al., 2005; Mi et al., 2004) . LINGO-1 is specific to the CNS and functions as a negative regulator of axonal regeneration and neuronal survival. We previously found that blocking the function of LINGO-1 protected a major proportion of injured RGCs in rats with ocular hypertension (Fu et al., 2008a) . LINGO-1 binds to the epidermal growth factor receptor to negatively regulates its activation (Inoue et al., 2007) . We just identified that LINGO-1 binds with BDNF receptor, TrkB and inhibits TrkB activation in vitro and in the rat retinas (Fu QL et al., unpublished data) . These data suggest that the negative regulatory functions of LINGO-1 may be involved in the limited neuroprotective effect of BDNF and it could be reversed after blocking the LINGO-1 function.
In this study, we investigated the combined neuroprotective effect of BDNF and a LINGO-1 antagonist, soluble LINGO-1 protein in a rat ocular hypertension model. We also investigated the involvement of TrkB activation with neuroprotection in this model.
EXPERIMENTAL PROCEDURES

Generation of recombinant LINGO-1-Fc
LINGO-1-Fc protein (soluble LINGO-1) was prepared as described previously (Mi et al., 2004) . Residues 1-532 of human LINGO-1 was fused to the hinge and Fc region of human IgG1, expressed in CHO cells and purified on Protein A Sepharose (Phamacia). The purified protein (> 95% pure) ran on SDS-PAGE with M r = 90 kDa under reducing conditions and M r = 180 kDa under non-reducing conditions.
Recombinant human BDNF was purchased from Regeneron Pharmaceutical (Tarrytown, NY). to prevent infection after the treatment. Rimadyl (0.025mg/ml, Pfizer, NY, USA) in drinking water was used to relieve the pain for 7 days after the surgeries.
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Ocular hypertension model and treatments
To induce experimental ocular hypertension, the rats received argon laser (Ultima 2000SE Argon Laser, Coherent, Palo Alto, CA) photocoagulation of the episcleral and limbal veins two times with 7 days apart in the right eye. This technique was adopted from the method by WoldeMussie et al (WoldeMussie et al., 2001 ) and has been used in our laboratory with a track record of publications (Fu et al., 2008b; Fu et al., 2008a; Ji et al., 2004; Li et al., 2006b; Li et al., 2006a) . About 90 spots were The protein solution was injected intravitreally into the right eye using a 10 µl
Hamilton microsyringe fixed with a 26-s gauge needle (#80300, Hamilton, Reno, Nevada, USA). The microsyringe was held inside the eyeball for more than 1 minute before being pulled out. The site of injection was just below of the limbus of the cornea, which provides minimal possibility of injury to the retina. The injections for combined proteins were performed at 30 min intervals.
Retrograde labeling of RGCs and RGC counting
In order to retrogradely label RGCs, both superior colliculi were exposed and a piece and also analyzed in terms of relative percent RGC loss in the injured right eye to the contralateral left intact eye from the same animal.
Immunohistochemistry for TrkB and LINGO-1
RGCs were retrogradely labeled with FG 7 days before sacrifice. The eyes were enucleated at 4 weeks after laser treatment following transcardial perfusion with 0.9% saline and were fixed in 4% paraformaldehyde for 1 h. After removing the cornea and lens, the eye cups were fixed further in paraformaldehyde for 4-6 h and then 
Western blotting
To measure the effects of BDNF and LINGO-1-Fc on TrkB phosphorylation, we injected recombinant human BDNF intravitreally (1 µg/injection) together with PBS (2µl) or BDNF together with LINGO-1-Fc (2 µg/injection) just after laser coagulation and then euthanized the animals 5 days later.
Retinas were dissected and homogenized in lysis buffer (10 mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA) supplemented with 10% protease inhibitor cocktail and 1% phosphatase inhibitor cocktails from Sigma. Following centrifugation at 13,000 rpm for 30 min to remove cell debris, the protein concentration of the supernatant was measured using a Bio-Rad DC protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 80 µg aliquot of proteins from each sample was subjected Promega, Mannheim, Germany) in 5% non fat dry milk and 2% bovine serum albumin for 2 h at room temperature and immunoreactive proteins were detected A C C E P T E D M A N U S C R I P T 9 using the enhanced chemiluminescence method (Amersham, Piscataway, NJ, USA).
The intensity of each band was quantified with densitometric scanning using Labworks gel documentation (UVP, Inc, Upland, CA). All experiments for western blotting were performed with 4-5 animals in each group and the samples from each animal were run on separate lanes. The levels of p-TrkB were finally expressed as relative values compared to total TrkB.
Statistics
The data were expressed as Mean ± SEM. Statistical analysis was performed by oneway analysis of variance followed by post-hoc tests (Turkey HSD) for comparisons of more than two groups or using paired Student's t test for comparisons between the right and contralateral left eyes in the same group. Data were analyzed statistically with the software SPSS 12.0. The mean difference is significant at 0.05 level.
RESULTS
Long-term RGC survival with the combined treatment of BDNF with LINGO-1 antagonist after ocular hypertension
Our previous findings that LINGO-1 negatively regulates TrkB function suggest that BDNF may activate more TrkB after blocking the function of LINGO-1. To determine the long-term effect of BDNF on RGC survival, we induced chronic ocular hypertension in rats and examined RGC survival 4 weeks after the induction of elevated IOP. The right eyes received a total of 4 intravitreal injections of proteins. As reported in our previous study (Fu et al., 2008a) , there was a significant loss of 20.9 ± 1.2% RGCs at 4 weeks after laser coagulation in animals receiving PBS injection ( Fig. 1B) . The treatment by BDNF and LINGO-1-Fc resulted in a significant reduction of the RGC loss in experimental eyes (one-way analysis of variance , F 3.28 = 31.48, P < 0.0001). Consistent with previous report (Ko et al., 2001) , four injections of BDNF only showed a partial neuroprotective effect on RGCs compared with PBS treatment group (P = 0.018, RGC loss, 15.3 ± 1.7%) (Fig. 1A) . Combined treatments with BDNF and LINGO-1-Fc rescued almost all of the RGCs compared with the BDNF+PBS group (P < 0.0001) and LINGO-1-Fc alone group (RGC loss, 8.8 ± 1.5%, P = 0.004) (Fig. 1A) . Blocking the function of LINGO-1 with LINGO-1-Fc significantly reduced RGC loss compared with PBS group (P < 0.0001, Fig. 1A ).
However, there was still a significant RGC loss with the LINGO-1-Fc treatment alone
[paired Student t-test between right and left eyes, t (7) = 2.431, P = 0.034] (Fig. 1B) .
In this study we also analyzed the data for RGC density between the treated eyes with normal eyes (Fig. 1C) . Similar conclusions were drawn after using the normal eyes as the control. The administration of PBS and BDNF resulted in a significant loss for RGCs compared to normal group (P < 0.0001). After the treatment of LINGO-1-Fc alone, more RGCs survived compared to PBS and BDNF treated eyes (P < 0.0001).
However, there was still RGC loss in LINGO-1-Fc group compared to normal group (P < 0.05). We have previously investigated the death of RGCs in our rat glaucoma 
TrkB Activation with the combined treatment of BDNF and LINGO-
1-Fc
To reveal whether BDNF could activate TrkB more efficiently in the presence of LINGO-1-Fc. we injected exogenous BDNF into the eye and studied the TrkB activation 5 days after the induction of ocular hypertension (Fig. 3A, B) . Normal rat 
Co-localization of TrkB and LINGO-1 in the retinal ganglion cells
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To further support the claim that LINGO-1-Fc supports BDNF to promote the activation of TrkB, we examined the co-localization of LINGO-1 and TrkB in the retina. The results presented in this study confirm our previous findings (Fu et al., 2008a ) that LINGO-1 was expressed in RGCs (Fig. 4A ) and up-regulated after the induction of ocular hypertension (Fig. 4B) . We found that there was moderate immunostaining for TrkB in the inner plexiform layer and in the ganglion cell layer in the normal retina (Fig. 4C ). TrkB expression increased at 4 weeks after the induction of ocular hypertension (Fig. 4D) . LINGO-1 and TrkB were co-expressed in the RGCs retrogradely labeled with FG ( Fig. 4E-H ).
DISCUSSION
Current neuroprotectants used to treat glaucoma only delay and do not prevent RGC death. This study showed that a combined treatment of BDNF and LINGO-1 antagonist provides long term RGC neuroprotection after the induction of elevated IOP. We further identified that a combination of BDNF and LINGOO-1-Fc accelerates TrkB activation in the eyes with elevated IOP. Our study suggests an effective strategy for the treatment of glaucomatous neuropathy.
Neuroprotective effects of combined application of BDNF and LINGO-1-Fc after ocular hypertension
The loss of RGCs in patients suffering from glaucoma appears progressively over 
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13 RGC death in human glaucoma. The major type of RGC death in glaucoma is probably apoptosis (Quigley et al., 1995) . Neurotrophin can hinder the induction of apoptotic cell death and promote RGC survival. However, several neuroprotectants such as BDNF, neurotrophin-3 and 4, insulin-like growth factor, glial cell-derived neurotrophic factor show only partial protective effects on RGCs after retinal injury (Kermer et al., 2000; Klocker et al., 1997; Peinado-Ramon et al., 1996) . Here we found that BDNF combined with LINGO-1-Fc resuced almost all of RGCs up to 4 weeks after ocular hypertension. Unlike the slow course of human chronic glaucoma, the loss of RGCs in this rat ocular hypertension model becomes stable after 4 weeks (Li et al., 2006a) . We have previously investigated the death of RGCs in our rat suggested to responsible for limiting the rescue effect of BDNF after retinal injury Ko et al., 2000) . However, a combined treatment of BDNF and antioxidants only showed partial survival of RGCs in the eyes of hypertensive rats (Ko et al., 2000) . It is possible that the RGCs lose the responsiveness of TrkB to BDNF after retinal injury, as has been observed in other neurons (Carter et al., 1995; Frank et al., 1996) . However, axotomized RGCs can express sufficient levels of TrkB (Di et al., 1998) and transferring the TrkB gene into RGCs combined with exogenous BDNF administration provided a transient increased neuronal survival after optic ACCEPTED MANUSCRIPT
14 nerve transection (Cheng et al., 2002 ). Here we found that the limited protection of BDNF on RGCs could be reversed after blocking of LINGO-1 function. We further identified a possible mechanism underlying this protective effect, as described in the following discussion.
We previously found that blocking LINGO-1 function promoted RGC survival in a rat ocular hypertenstion model. However, there was still some RGC loss at 4 weeks after the induction of ocular hypertension. In this study we found that the effect of a combined treatment of BDNF and LINGO-1-Fc on RGC survival in this animal model of ocular hypertension is better than LINGO-1-Fc alone. It suggests LINGO-1-Fc has limited neuroprotection.
The effect of combined application of BDNF and LINGO-1-Fc on TrkB activation after ocular hypertension
Here we found that a combined treatment of BDNF and LINGO-1-Fc could activate more TrkB compared to BDNF alone. Neurotrophins can activate two types of receptors, the Trk family and p75 receptor (Huang and Reichardt, 2003) . Trk receptors consist of a family of three receptor tyrosine kinases, TrkA, TrkB and TrkC, each of which can be activated by respective neurotrophins. TrkB is the dominant Trk receptors in the retina. BDNF exerts its neuroprotective activity by activating TrkB.
The p-TrkB subsequently activates the downstream signaling pathway such as PI-3K/Akt (Huang and Reichardt, 2003) . These data suggest that LINGO-1 may negatively regulate the activity of BDNF and TrkB. We just identified that LINGO-1 binds with TrkB and negatively regulates its activation in a culture system of RGCs and in the retina of rats (Fu QL et al., unpublished data) . These data suggest a possible molecular mechnism that the partial neuroprotection of BDNF may largely
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15 attributable to negative regulation of LINGO-1 to the BDNF-TrkB signaling receptor.
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CONCLUSIONS
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